Skip to content

BCBS Rhode Island

Does BCBS Rhode Island cover Zepbound?

Yes. BCBS Rhode Island covers Zepbound for weight loss with prior authorization if your BMI is 30 or higher, or 27 or higher with a related condition. Other policy requirements and your plan's benefits also apply.

Policy document

  • Employer and ACA Marketplace: Covered with requirements. See the qualification pathways below.

Earliest policy review June 2, 2026. How we verify · Check your exact plan

Full requirements: Zepbound for Weight Loss (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Adult obesity

All of:

  • Age ≥ 18 years
  • BMI ≥ 30 kg/m2

Adult overweight with comorbidity

All of:

  • Age ≥ 18 years
  • BMI ≥ 27 kg/m2

Plus any one of:

  • Hypertension
  • T2DM
  • dyslipidemia
  • OSA
  • CVD
  • MASH

Asian adult overweight/obesity

All of:

  • BMI ≥ 23 kg/m2 (South Asian, Southeast Asian, or East Asian adults)

Documentation to bring

  • Baseline BMI documentation (≥ 30 kg/m2 for obesity, or ≥ 27 kg/m2 for overweight)
  • Documentation of weight-related comorbidity if BMI 27–29.9 kg/m2
  • Age documentation (≥ 18 years)

Approval and renewal

  • Renewal: Continuation recommended only for patients achieving at least 5% weight loss and tolerating therapy, assessed after 12 weeks at a therapeutic dose.
  • Renewal: At least 12 weeks on therapy before the first renewal.

Not covered when

  • Coadministration with other tirzepatide-containing products not recommended
  • Coadministration with any GLP-1 receptor agonist not recommended

Policy note: Available as both subcutaneous injection solution vial and Kwikpen formulations. Efficacy assessed after 12 weeks at therapeutic dose; continuation only if ≥ 5% weight loss achieved and therapy tolerated.

Policy effective May 4, 2026 · verified June 2, 2026 · source: Ri Weight Management Prog Sum · View policy document (PDF)

Open on its own page →

Full requirements: Zepbound for Obstructive Sleep Apnea (OSA) (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Moderate to severe OSA with obesity

All of:

  • Adult (age ≥ 18 years)
  • BMI ≥ 30 kg/m2 (obesity)
  • Diagnosis of moderate to severe OSA (AHI ≥ 15 events/hour or REI/RDI equivalent per PSG or HSAT)

Plus any one of:

  • Patient not currently receiving PAP therapy
  • Patient currently receiving PAP therapy (both populations studied in SURMOUNT-OSA)

Documentation to bring

  • Diagnosis of moderate to severe OSA confirmed by polysomnography (PSG) or home sleep apnea testing (HSAT)
  • AHI, REI, or RDI result documenting moderate to severe OSA (AHI ≥ 15 events/hour)
  • Baseline BMI ≥ 30 kg/m2 (obesity)
  • Age ≥ 18 years

Not covered when

  • Craniofacial abnormalities affecting respiration (per SURMOUNT-OSA exclusion criteria)
  • Predominantly central or mixed sleep apnea (≥ 50% central or mixed apneas/hypopneas)
  • Cheyne-Stokes respiration
  • Obesity hypoventilation syndrome
  • Evidence of daytime hypercapnia
  • Coadministration with other tirzepatide-containing products not recommended
  • Coadministration with any GLP-1 receptor agonist not recommended

Policy note: FDA indication is for moderate to severe OSA in adults with obesity. The SURMOUNT-OSA program (two Phase 3 trials) enrolled participants with mean AHI ~50 events/hour and mean BMI ~39 kg/m2. Trial 1 enrolled patients not on PAP therapy; Trial 2 enrolled patients on PAP therapy. The document notes AHI from PSG is the preferred diagnostic index; REI (HSAT-based) is acceptable surrogate but may underestimate severity; RDI may identify arousal-based disease. PAP therapy trial is NOT required as a prerequisite per the clinical rationale. OSA AHI minimum set to 15 events/hour based on the definition of moderate OSA (the FDA indication requires 'moderate to severe'). AASM recommended hypopnea scoring: ≥ 3% oxygen desaturation and/or arousal.

Policy effective May 4, 2026 · verified June 2, 2026 · source: Ri Weight Management Prog Sum · View policy document (PDF)

Open on its own page →

Questions people ask
Does BCBS Rhode Island cover Zepbound?
Yes. BCBS Rhode Island covers Zepbound for weight loss with prior authorization if your BMI is 30 or higher, or 27 or higher with a related condition. Other policy requirements and your plan's benefits also apply.
What does BCBS Rhode Island require to renew Zepbound?
Weight Loss — Applies to Employer and ACA Marketplace plans. Continuation recommended only for patients achieving at least 5% weight loss and tolerating therapy, assessed after 12 weeks at a therapeutic dose. At least 12 weeks on therapy before the first renewal.
How current is this information?
The oldest review date among the policies on this page is June 2, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under BCBS Rhode Island: Mounjaro, Ozempic, Wegovy

Zepbound under other plans: BCBS Alabama, BCBS Arizona, BCBS Arkansas, BCBS Massachusetts, BCBS Michigan, BCBS Minnesota, BCBS Nebraska, BCBS North Carolina

All insurance plans · All medications

Summary of BCBS Rhode Island's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.